The Biden administration on Thursday asserted its authority to seize the patents of certain costly medications in a new push to slash high drug prices and promote more pharmaceutical competition.
The administration unveiled a framework outlining the factors federal agencies should consider in deciding whether to use a controversial policy, known as march-in rights, to break the patents of drugs that were developed with federal funds but are not widely accessible to the public. For the first time, officials can now factor in a medication’s price — a change that could have big implications for drugmakers depending on how the government uses the powers.
“When drug companies won’t sell taxpayer-funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard said during a call with reporters Wednesday.
With the R’s and D’s history of both being completely owned by the same oligarchs in mind, this sounds like a framework that will be used to crush smaller pharmaceutical companies and give patents to the all ready huge ones… I might just be super critical, correct me if I’m wrong…
It’s not like there is a cottage industry of small time pharmaceutical companies these days. The smaller ones that exist mostly just focus on making generic forms of drugs that jave expired patents.
Yes, true, but what i’m trying to ask is; is there any safeguard in the bill preventing it from being used to crush the few smaller ones?